PNPLA3 and fatty liver disease: The impact of short-term omega-3 fatty acid supplementation on hepatic steatosis in carriers of the PNPLA3 rs738409 variant was not found to be significant [40], but it seems that reducing n-6/n-3 PUFAs can reduce hepatic fat fraction percentage in individuals with the rs738409 risk allele, regardless of weight loss [45,47].